INTRODUCTION
============

Clozapine use is associated with various adverse events.[@B1] The associations of eosinophilia, hepatitis, and pleural effusion with clozapine have received little attention because these conditions are considered to be rare or not life-threatening side effects.

The incidence of eosinophilia associated with clozapine has been reported to range from 0.2% to 62%.[@B2] Eosinophilia usually develops during the initial phase, between weeks 3 and 5 of clozapine use, and follows a transient course characterized by spontaneous remission. However, eosinophilia has been associated with major organ involvement such as hepatitis.[@B3]

Elevation of liver enzymes secondary to clozapine use is common and affects 30-50% of patients.[@B4] It is usually transient and detected accidentally. The onset of liver toxicity is usually 4-5 weeks after initiating clozapine therapy.[@B4] However, a few patients with clozapine-induced jaundice were reported to have died as a result of fulminant hepatic failure.[@B5]-[@B7]

It is necessary to understand the course and management of clozapine-induced eosinophilia and hepatitis. We discuss a patient who developed eosinophilia at the beginning of clozapine use and then successively developed pleural effusion and jaundice with hepatitis.

CASE
====

Ms. A, a 47-year old woman with a 15-year history of schizophrenia, was hospitalized after noncompliance with antipsychotic medications, which resulted in decompensation characterized by aggressive behavior, auditory hallucinations and delusions. All laboratory tests performed on admission, including complete blood cell count (CBC), serum electrolytes, urinalysis, and liver function tests (LFTs), were within normal limits. Hepatitis serology revealed that the hepatitis B surface (HBs) antibody was positive and that the HBs antigen was negative. Ms. A was a non-smoker and non-drinker with no history of substance misuse and no significant medical history.

Due to poor responses to previous antipsychotic treatments, the patient was started on clozapine with the dose titrated from 12.5 mg/day to 300 mg/day during a 4-week period. During this period the patient had no other medications.

The weekly checks of the CBC showed gradual increases in the eosinophil count following the beginning of clozapine treatment. The eosinophil count was 0.9% (57/mm^3^) before clozapine use, 1.7% (142/mm^3^) at day 8, 2.8% (248/mm^3^) at day 15, and 5.0% (416/mm^3^) at day 22. On day 29, the total leukocyte count increased to 10,910/mm^3^, and the eosinophilia reached 23.6% (2,575/mm^3^). Ms. A did not have any symptoms.

On day 35, the patient complained of general myalgia and 37.5℃ fever. Both leukocytosis (16,500/mm^3^) and eosinophilia (28.9%, 4,769/mm^3^) were aggravated. A chest X-ray revealed some amount of right side pleural effusion. The pleural effusion was considered to be the cause of the fever and leukocytosis, and conservative management of oral antibiotics was provided. Because clozapine was effective in managing the psychotic symptoms, it was maintained at the reduced dosage of 100 mg/day. On day 42, the total leukocyte count was normalized, at 9,230/mm^3^ but the eosinophil count had increased to 54.2% (5,003/mm^3^). She showed an intermittent 37.7℃ fever, but general myalgia had disappeared. On day 44, a repeat chest X-ray revealed that the pleural effusion had nearly disappeared, and the fever had subsided. The total leukocyte and eosinophil count decreased to 8,350/mm^3^ and 40.1% (3,348/mm^3^), respectively.

On day 48, the patient suddenly became jaundiced, and she was transferred to the department of internal medicine at a general hospital. The total leukocyte count was 3,600/mm^3^ with 12.9% (464/mm^3^) eosinophil. The LFTs were notable for the following abnormalities: alanine transaminase (ALT) 254 IU/L (range, 4-43), aspartate transaminase (AST) 277 IU/L (range, 7-38), r-glutamyl-transferase (GGT) 573 U/L (range, 8-48), total bilirubin 6.0 mg/dl (range, 0.2-1.2), and direct bilirubin 3.5 mg/dl (range, 0.1-0.4). Abdominal computed tomography showed hepatopathy by acute hepatitis. The urinalysis showed urobilinogen 2+ (range, trace). The patient retrospectively reported that her urine color had changed to red during the previous 2 weeks.

After 5 days without clozapine, the LFTs improved, showing an ALT level of 22 IU/L, an AST level of 37 IU/L, a GGT level of 46 U/L, a total bilirubin of 0.6 mg/dl, and a direct bilirubin of 0.2 mg/dl. The total leukocyte count was 4,200/mm^3^ with 10.5% (441/mm^3^) eosinophil. Ms. A was readmitted to our hospital after 1 week without clozapine for treatment of psychotic symptoms. The total leukocyte count was 4,400/mm^3^ with 3.4% (150/mm^3^) eosinophil on the day of readmission. There were no recurrences of LFT or CBC abnormalities during following treatment with olanzapine and haloperidol.

DISCUSSION
==========

In this case, the eosinophil count began to increase shortly after clozapine use and reached its peak level at week 5-6, and since then, the eosinophil count gradually decreased. Pleural effusion and red colored urine developed at week 5 and jaundice developed around at week 7 when the eosinophilia was nearly disappeared.

Benign eosinophilia is peripheral eosinophilia noted shortly after clozapine administration without other evidence of inflammatory processes. Some patients with eosinophilia have experienced inflammation of major organs such as pancreatitis[@B8] and a few cases with more severe forms of multi-organ involvement have been reported.[@B9],[@B10]

In cases in which eosinophilia is accompanied by the involvement of major organs, clozapine should be discontinued immediately. On the other hand, it does not seem necessary to discontinue clozapine if benign eosinophilia develops. The Sandoz guidelines[@B11] recommend that clozapine be discontinued when eosinophil counts exceed 4,000/mm^3^, and that it not be resumed until they are lower than 3,000/mm^3^.

Several previous reports have shown that clozapine-induced hepatitis frequently accompanies eosinophilia. However, none of the three fatal cases of hepatic failure found comorbid eosinophilia.[@B5]-[@B7] Considering our case, it is possible that fulminant hepatitis including jaundice may develop after eosinophilia subsides. That is, the timing of abnormal LFTs may coincide with eosinophilia. Additional monitoring of eosinophil during mandatory weekly leukocyte follow-up visits may be helpful for detecting LFT elevations during early stage.

The Sandoz guidelines indicate that clozapine should be discontinued if any LFT increases which is clinically relevant or if symptoms of jaundice occurs. After normalization of LFTs, some patients were able to restart clozapine,[@B11] but some were not able to do so.[@B12] Most patients who developed jaundice did not restart clozapine.

Associations between clozapine and pleural disease are rare. Pleural effusions associated with clozapine have usually been associated with other systemic manifestations such as pericardial effusion.[@B13]

In our case, pleural effusion was accompanied by fever and leukocytosis and subsided after antibiotic therapy; thus, parapneumonic effusion is probable. However, red-colored urine, fever, pleural effusion, and the peak eosinophil count were observed at around the same time. Some reports have described multi-organ idiosyncratic responses to clozapine, such as eosinophilia, pleural effusion, hepatitis, cholecystitis, ascitis, and hematuria during clozapine use.[@B9]-[@B10]

Therefore, we recommend that patients who develop rapid eosinophilia at the beginning of clozapine treatment should be monitored with LFTs, chest X-rays, and urine analysis tests.
